Gastroparesis Drugs Market

Gastroparesis Drugs Market Size (2023 to 2028)

The global gastroparesis drugs market is forecasted to grow at a CAGR of 4.8% during the forecast period. As a result, the size of the market is predicted to be worth USD 7.24 billion by 2028 from USD 5.73 billion in 2023.

MARKET DRIVERS:

The growing geriatric population prone to gastroparesis worldwide and the rising prevalence of gastroparesis among the population propel the gastroparesis drugs market. According to the Economic and Social Commission for Asia and the Pacific (ESCAP), an estimated 670 million people will be above the age of 60 years in 2022 in the Asia-Pacific region, which holds 14% of the entire population of APAC. The increasing patient population with diabetes and the introduction of new drugs to control symptoms such as nausea are majorly driving the global gastroparesis drugs market. According to International Diabetes Federation, an estimated 537 adults had diabetes in 2021, which is anticipated to reach 643 million by 2030. The increase in the number of surgeries leading to post-surgical gastroparesis conditions and the growing commonness of diabetic Mellitus in people, as rising R&D activities by the manufacturers to produce more advanced drugs required to treat Gastroparesis, is further expanding the market growth. The National Institute of Health (NIH) revealed that type I diabetes quickly affects many children and teenagers. The growing number of hospitals with well-equipped, furnished healthcare infrastructure and climbing healthcare expenses mount the market growth. 

The various medications developed to target gastroparesis disease are expected to support market growth. Medications like Metoclopramide, Erythromycin, Domperidone, Cisapride, Antiemetics, Tricyclic Antidepressants, Pain Medicines, Gastric Electrical Stimulation, etc., are all highly reliable for the condition prompting efficient treatment. All these drugs have various specific purposes. For example, Heartburn brought on by gastroesophageal reflux disease is treated temporarily with metoclopramide. Erythromycin has been used orally and intravenously for its prokinetic effect (IV). Domperidone, a dopamine two antagonist, is only available through a specific program run by the FDA and is used to treat nausea, vomiting, and complaints of the stomach that occur with delayed emptying in patients whose symptoms do not respond to metoclopramide. Cisapride is a 5-HT4 agonist that promotes antral and duodenal motility and speeds up the emptying of the stomach's contents. Antiemetic drugs include those that reduce nausea and vomiting. It has been shown that taking nortriptyline at low doses reduces the symptoms of nausea, vomiting, and abdominal pain. Nortriptyline is a tricyclic antidepressant with little anticholinergic effects. Therefore, the various applications of these wide-ranged drugs promote market growth. 

The growing awareness about gastroparesis and available treatment options, an increasing number of advancements in diagnostic technologies for gastroparesis, rising number of R&D activities for novel gastroparesis drugs, increasing healthcare expenditure and growing support from governmental organizations for gastroparesis management contribute to the market growth. The introduction of innovative drug delivery systems for gastroparesis treatment, improving healthcare infrastructure and facilities specializing in gastroparesis treatment and increasing demand for effective and safe medications to manage gastroparesis symptoms further fuel the growth rate of the global gastroparesis drugs market.

MARKET RESTRAINTS:

The poor understanding of gastroparesis and its underlying causes is one of the leading factors hampering the market growth. The lack of effective and targeted treatment options for gastroparesis and challenges in the diagnosis and detection of gastroparesis hinder market growth. The high cost of gastroparesis drugs, limited affordability, adverse side effects associated with certain gastroparesis medications and regulatory challenges and delays in drug approvals further impede the market growth. Insufficient reimbursement policies for gastroparesis drugs, limited awareness among healthcare professionals and patients about available treatment options, lack of specific guidelines for the management of gastroparesis and the presence of alternative treatment modalities are some other notable roadblocks to the growth rate of the global market.

Impact of COVID-19 on the global gastroparesis drugs market:

The COVID-19 pandemic has disrupted the supply chain management of over-the-counter (OTC) and prescription drugs, impeding market growth in the next few months. Medical healthcare professionals mainly concentrate on COVID-19, which led to less focus on diagnosing and treating Gastroparesis, restraining the market's growth. COVID-19 has created an adverse effect on the gastroparesis drugs market. The first COVID-19 case reported in the United States has developed the G.I. symptoms like vomiting and diarrhea. It is mandatory for clinicians, extremely gastroenterologists, to be conscious of typical and rarely missed presentations of COVID-19. The unfavorable drug can be another feasible explanation. Some antivirals, antibiotics, and immunomodulators prescribed to COVID-19 patients cause diarrhea—the high commonness of G.I. symptoms reported in the studies. 

REPORT COVERAGE:

This research report on the global gastroparesis drugs market has been segmented and sub-segmented based on the type, production technologies, and region.

Gastroparesis Drugs Market – By Drug Class:

• Prokinetic Agents 
• Antiemetic Agents
• Botulinum Toxin Injections 

Based on drug class, the prokinetic agent is expected to lead the global gastroparesis drugs market during the forecast period. The prokinetic agent is used to ease gastrointestinal symptoms like bloating, constipation, abdominal discomfort and vomiting. The growing prevalence of gastroparesis and related symptoms, increasing demand for medications that improve gastric motility and emptying and the growing number of advancements in prokinetic agents with improved efficacy and safety profiles drive the segmental growth. The growing awareness and diagnosis of gastroparesis, increasing R&D activities in prokinetic drug development and the availability of various prokinetic agents with different mechanisms of action further boost the growth rate of the segment.

The botulinum toxin injections segment is estimated to witness the highest CAGR and is expected to maintain its dominance during the forecast period. Botox injections are used to treat fine lines and wrinkles and therefore are popular among populations for youthful skin treatments. Botulinum toxin injections offer a targeted treatment approach for gastroparesis. The growing adoption of minimally invasive procedures for gastroparesis management, potential benefits of botulinum toxin injections in improving gastric emptying, growing research and clinical trials to explore the efficacy of botulinum toxin in gastroparesis and rising demand for alternative treatment options in refractory or severe cases of gastroparesis contribute to the growth of the botulinum toxin injections segment.

Gastroparesis Drugs Market – By Disease Class:

• Diabetic Gastroparesis 
• Idiopathic Gastroparesis
• Post-surgical Gastroparesis
• Others

Based on disease class, the idiopathic gastroparesis segment is estimated to account for the major share of the global market during the forecast period. The growing number of advancements in novel and efficient therapies for the diagnostic control of idiopathic gastroparesis is one of the major factors propelling the segmental growth. The growing rising diabetes mellitus population worldwide leads to high demand for diagnosis and treatment, and diabetes is a common cause of gastroparesis, drive the segmental growth. The growing recognition and diagnosis of idiopathic gastroparesis, rising research efforts to understand the underlying causes, increasing demand for targeted therapies to manage symptoms in idiopathic gastroparesis and rising focus on improving the quality of life for patients with idiopathic gastroparesis further fuel the growth rate of the idiopathic gastroparesis segment.

The post-surgical gastroparesis segment is projected to showcase a healthy CAGR during the forecast period owing to the growing number of surgeries such as transplantations. An increasing number of gastrointestinal surgeries globally, increased risk of gastroparesis as a complication of surgery, growing demand for effective treatments to manage post-surgical gastroparesis symptoms and increasing number of advancements in surgical techniques to reduce the incidence of post-surgical gastroparesis contribute to the segmental growth.

Gastroparesis Drugs Market – By End User:

• Hospitals
• Pharmacies 
• Clinics 
• E-commerce

Based on end-user, the hospital segment is predicted to hold the leading share of the global market during the forecast period. The availability of specialized healthcare professionals and infrastructure for diagnosing and treating gastroparesis, the growing number of hospitalized patients with gastroparesis or related conditions and the presence of advanced medical facilities for administering drugs and monitoring patient response majorly drive the growth of the hospital segment. The growing number of collaborations between hospitals and pharmaceutical companies for clinical trials and research and strong referral network and access to a wide patient pool further support the segmental growth.

The pharmacy segment is predicted to grow at a healthy CAGR during the forecast period. Factors such as the easy accessibility for patients to purchase gastroparesis drugs and related medications, expansion of retail pharmacy chains and online pharmacy platforms, the growing awareness of gastroparesis and self-management of symptoms, convenience and availability of over-the-counter medications and increasing number of prescriptions being filled for gastroparesis drugs primarily propel the growth of the pharmacy segment.

Gastroparesis Drugs Market – By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

The gastroparesis drugs market in North America accounted for the largest share of the global market in 2022. The high prevalence of gastroparesis in the North American region, the availability of advanced healthcare infrastructure and access to specialized gastroenterology clinics and the growing awareness and diagnosis of gastroparesis primarily drive the growth of the North American market. Strong presence of key pharmaceutical companies conducting research and development activities and favorable reimbursement policies for gastroparesis drugs and related treatments further boost the growth rate of the North American market. The U.S. held the major share of the North American market in 2022 and the domination of the U.S. in the North American region is likely to continue during the forecast period owing to the growing prevalence of gastroparesis and adoption of prokinetic agents, such as metoclopramide and domperidone.

The gastroparesis drugs market in Europe had the second-largest share of the global market in 2022 and is estimated to hold a substantial share of the European market during the forecast period. The growing prevalence of diabetes and underlying gastrointestinal disorders, increasing number of advancements in healthcare infrastructure and specialized clinics for gastroparesis management primarily propel the European market growth. The growing investments in research and development activities related to gastroparesis drugs, strong focus on patient-centric care and improving quality of life for gastroparesis patients and favorable government initiatives supporting the diagnosis and treatment of gastroparesis further boost the growth rate of the European market. Germany followed by the UK had the major share of the European market in 2022 and same pattern is predicted to continue throughout the forecast period.

The Asia Pacific gastroparesis drugs market is the fastest-growing regional market and is anticipated to remain so in the forecast period. Emerging economies of India and China are spearheading this growth spurt. The Asia-Pacific region exhibits gainful opportunities for many companies as India has a high standard pace of diabetes, leading to gastroparesis disorder contributing a significant share in the market. Furthermore, initiatives to assist product approvals and labeling claims for diabetic gastroparesis treatments provide profitable opportunities for the market players. In addition, vast unused market potential among emerging countries like China and India and the advancement of novel gastroparesis drugs provide gainful opportunities to the market players. 

The gastroparesis drugs market in Latin America is projected to grow at a healthy CAGR during the forecast period. The growing prevalence of diabetes and obesity in Latin America, improving healthcare infrastructure, increasing access to specialized gastroenterology clinics and growing awareness and diagnosis of gastroparesis majorly propel the Latin American market growth. An increasing number of initiatives by the Latin American governments to improve healthcare services and address gastrointestinal disorders and expansion of pharmaceutical companies in the Latin American region focusing on gastroparesis drugs further boost the growth rate of the Latin American market. Brazil led the market in Latin America in 2022.

The MEA gastroparesis drugs market is anticipated to progress at a steady CAGR in the coming days.

KEY MARKET PARTICIPANTS:

Some of the most prominent companies dominating the Global Gastroparesis Drugs Market profiled in this report are Bayer HealthCare AG, Bioniche Animal Health Canada, Sanofi Animal Health, Inc., Biogenesis Bago SA, Heska Corporation, Indian Immunologicals Ltd., Boehringer Ingelheim GmbH, Zoetis, Novartis Animal Health, Inc., Merck & Co. Inc. and Protein Sciences.

RECENT MARKET HAPPENINGS:

• In January 2017, Soliqua 100/33 (insulin glargine 100 Units/ml& lixisenatide 33mcg/mL injection) by Sanofi, available in U.S pharmacies the treatment of adults with type 2 diabetes.
• In December 2018, Vanda Pharmaceuticals, Inc. declared tradipitant met the primary endpoint VLY686-2301, a phase-II clinical study among patients with idiopathic and diabetic gastroparesis.